MDxHealth SA (MDXH): Price and Financial Metrics

MDxHealth SA (MDXH): $2.74

0.07 (-2.49%)

POWR Rating

Component Grades

Momentum

F

Stability

C

Sentiment

Quality

D

MDXH Price/Volume Stats

Current price $2.74 52-week high $4.64
Prev. close $2.81 52-week low $2.15
Day low $2.70 Volume 24,409
Day high $2.78 Avg. volume 65,055
50-day MA $2.70 Dividend yield N/A
200-day MA $3.06 Market Cap 4.27M

MDXH Stock Price Chart Interactive Chart >


MDxHealth SA (MDXH) Company Bio


MDxHealth SA operates as a molecular diagnostics company in Belgium, the Netherlands, Spain, Poland, Italy, the United States, rest of European Union, and internationally. The company develops and commercializes epigenetic and other molecular tests for cancer assessment and the personalized treatment of patients. Its tests are based on proprietary genetic, epigenetic, and other molecular technologies, as well as assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The company's product pipeline includes tests for bladder, kidney, and other urologic cancers. Its products include ConfirmMDx, a tissue test for prostate cancer; and SelectMDx, a non-invasive urine test for prostate cancer. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.


MDXH Latest News Stream


Event/Time News Detail
Loading, please wait...

MDXH Latest Social Stream


Loading social stream, please wait...

View Full MDXH Social Stream

Latest MDXH News From Around the Web

Below are the latest news stories about MDXHEALTH SA that investors may wish to consider to help them evaluate MDXH as an investment opportunity.

MDxHealth Announces Completion of Transition to Single Listing on Nasdaq

NEWS RELEASE – REGULATED INFORMATIONDECEMBER 18, 2023, 1:00 AM ET / 07:00 AM CET MDxHealth Announces Completion of Transition to Single Listing on Nasdaq IRVINE, CA, and HERSTAL, BELGIUM – December 18, 2023 – MDxHealth SA (NASDAQ/Euronext Brussels: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announces the completion of its transition to a single listing on Nasdaq. In accordance with prior announcements made by the Company and the corporate event

Yahoo | December 18, 2023

MDxHealth Announces Completion of Mandatory ADS Exchange and Commencement of Transition Period to Single Listing on Nasdaq

NEWS RELEASE – REGULATED INFORMATIONNOVEMBER 27, 2023, 1:00 am ET / 7:00 am CET MDxHealth Announces Completion of Mandatory ADS Exchange and Commencement of Transition Period to Single Listing on Nasdaq IRVINE, CA, and HERSTAL, BELGIUM – November 27, 2023 – MDxHealth SA (NASDAQ/Euronext Brussels: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announces the completion of the mandatory exchange under the Company's American Depositary Shares ("ADSs") f

Yahoo | November 27, 2023

MDxHealth to Participate in the 35th Annual Piper Sandler Healthcare Conference

NEWS RELEASENovember 14, 2023, 4PM ET/ 22:00 CET MDxHealth to Participate in the 35th Annual Piper Sandler Healthcare Conference IRVINE, CA, and HERSTAL, BELGIUM – November 14, 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH), a commercial-stage precision diagnostics company, today announced that Michael K. McGarrity, Chief Executive Officer, will participate in a fireside chat at the 35th Piper Sandler Healthcare Conference on Wednesday, November 29, 2023, at 9:00am ET. A live webcast o

Yahoo | November 14, 2023

MDxHealth Announces Completion of Share Consolidation, and Update of Outstanding Shares and Voting Rights

NEWS RELEASE - REGULATED INFORMATIONINSIDE INFORMATIONNOVEMBER 13, 2023, 4:00 PM ET / 22:00 CET MDxHealth Announces Completion of Share Consolidation, and Update of Outstanding Shares and Voting Rights IRVINE, CA, and HERSTAL, BELGIUM – November 13, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) ("mdxhealth" or the "Company"), a commercial-stage precision diagnostics company, today announces that it completed the share consolidation with respect to all its outstanding shares by means of a 1-for-10

Yahoo | November 13, 2023

MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2023

NEWS RELEASE – REGULATED INFORMATION8 NOVEMBER 2023, 4:00PM EDT / 22:00 CET MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2023 IRVINE, CA, and HERSTAL, BELGIUM – November 8, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today announced its financial results for the third quarter and nine-month period ended September 30, 2023. Michael K. McGarrity, CEO of mdxhealth, commented: “We are pleased to report st

Yahoo | November 8, 2023

Read More 'MDXH' Stories Here

MDXH Price Returns

1-mo -4.86%
3-mo 7.87%
6-mo -26.93%
1-year -26.15%
3-year N/A
5-year N/A
YTD -30.46%
2023 -40.39%
2022 -30.57%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!